Andrew is a senior M&A and equity capital markets lawyer with extensive experience in public and private mergers and acquisitions, IPOs and secondary offerings, joint ventures and private financing rounds.

He is one of only six London lawyers to be ranked in Tier 1 for mid-market M&A by Chambers UK legal directory as well as being listed as one of The Lawyer's Hot 100. As quoted in the legal directories, Andrew's clients describe him as 'a strong negotiator and problem solver' as well as being 'Incredibly pragmatic. The perfect sounding board for our business.'

Andrew is the UK Head of Corporate Life Sciences and is recognised within the legal directories as a 'very talented' corporate and commercial lawyer with a long-standing commitment to the biotechnology and pharmaceutical industries.

While at his previous firm, Andrew led the team on the contested public takeover of his long-standing client Lavendon Group plc, a transaction which garnered industry recognition at The Legal Business Awards.

显示完整简历 隐藏完整简历

最新新闻和观点

酒店与休闲

Aspen Healthcare sold to Canadian-based property trust

2021年9月27日

作者 Andrew McLean 以及 Andrew Edge

点击此处了解更多
酒店与休闲

Advising Apollo Therapeutics on $145 million financing

2021年6月21日

作者 Andrew Edge 以及 Chris Cowley

点击此处了解更多
公司/并购与资本市场

Taylor Wessing advises Topp Holdings on the sale of its Belgian Runtime Group to Umani Group

2022年8月10日

作者

点击此处了解更多
公司/并购与资本市场

Advising Azenta, Inc. on its acquisition of B Medical Systems

2022年8月9日

作者 William Belcher

点击此处了解更多

与我会面: